MedTrace Logo

Treatment With Ribavirin for Patients With Metastatic Breast Cancer

NCT01056757 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-11-04

No results posted yet for this study

Summary

The purpose of this study is to learn whether oral Ribavirin is safe and effective in treating patients with metastatic breast cancer, that have high levels of eIF4E.

Conditions

Interventions

DRUG

Ribavirin

1000 mg bid, po, q28days

Sponsors & Collaborators

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • Wilson Miller, MD, PhD · Jewish General Hospital

  • Katherine Borden, PhD · Université de Montréal

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056757 on ClinicalTrials.gov